ibd_ce

Your only source for joint-accredited, serialized tweetorials on optimal management of inflammatory bowel disease. Physicians, nurses, pharmacists: join us!

[ibd_ce @ibd_ce]

You have found it! Your source for 🆓CE/CME via Twitter! Each program provides 0.5h credit for #physicians, #pharmacists, and #nurses on #IBD. Expert authors! See archived programs at https://t.co/YtRA0L3dMt.

[@onc_ce @onc_ce]

33) @SagarLonialMD adds: This is a very important study, the 1st randomized demonstration that #CELMoDs can partner well w/other agents & demonstrates superior #PFS vs a standard control arm. The 18mo #PFS for a relatively simple tx delivery process ➡️a great new option for pts.

[@onc_ce @onc_ce]

31) Safety was consistent w/prior #Mezi data; no new signals. Most common grade 3/4 AE: #neutropenia (61.1%), manageable with dose modifications and/or G-CSF; only 1 pt discontinued due to it. Importantly, most infections were NOT associated with grade 3/4 neutropenia. #ASCO2026

[@onc_ce @onc_ce]

30) Beyond 1st progression: #MeziKd also showed superior #PFS2 (23.6 vs 13.0 mo; HR 0.53), w/only 24% of MeziKd pts requiring subsequent therapy vs 50% on #Kd. #OS data remain immature (HR 0.79), with no crossing of curves at this early futility analysis.
#ASCO2026 #SUCCESSOR2

[@onc_ce @onc_ce]

29) Responses were deep and durable. #ORR: 80.2% (#MeziKd) vs 53.4% (#Kd). Mezi doubled the rate of ≥ #VGPR (60.1% vs 30.9%) and tripled the rate of ≥ #CR (26.7% vs 8.9%). 12-month duration of response: 72% vs 54%. #MRD analysis is ongoing.
#ASCO2026 #SUCCESSOR2 #RRMM

[@onc_ce @onc_ce]

28) The #PFS benefit was consistent across ALL prespecified subgroups, regardless of age, #ISS stage, #cytogenetic risk, refractory status (anti-CD38, #LEN, or both), number of prior LOTs, or presence of extramedullary disease. No subgroup favored Kd.
#ASCO2026 #SUCCESSOR2

[@onc_ce @onc_ce]

27) The headline result: #MeziKd reduced the risk of progression or death by 52% vs #Kd (HR 0.48; 95% CI 0.36–0.63; P<0.0001). Median #PFS 18.0 vs 8.3 months — more than double. This is the first positive Ph 3 #CELMoD trial to report.
#ASCO2026 #SUCCESSOR2 #myeloma

[@onc_ce @onc_ce]

22) Why does this trial matter? More #MM pts arrive at relapse already exposed to anti-CD38 mAbs AND lenalidomide. That dual exposure carries a median PFS of just 6.3 mo, so highly effective, convenient options for these pts are urgently needed. #ASCO2026 #SUCCESSOR2

[@onc_ce @onc_ce]

21b) ... as it is in #SUCCESSOR_2 (where the #proteasome inhibitor #PI is #carfilzomib), but in other trials it is combined with the PI #bortezomib, or in a triplet regimen with #daratumumab.

[@onc_ce @onc_ce]

21a) As shown, both drugs are being actively studied in #RRMM; #Iberdomide in combo with #daratumumab, a targeted monoclonal antibody #MAb used to treat #MM & #AL_amyloidosis.
#Mezigdomide is primarily used in combo with dexamethasone & a proteasome inhibitor ...

[@onc_ce @onc_ce]

20) The #CELMoD mechanism of action #MOA was reviewed to set the scene for those in attendance: as we saw ⤴️, #iber and #mezi deliver superior #MM cell killing and immune stimulation, compared to #IMiDs.
Need a refresher? Go to 🔓https://t.co/TJhy2uKTJm

[@onc_ce @onc_ce]

19) Your faithful correspondent and #MM expert faculty @SagarLonialMD was in the room at #ASCO26 on behalf of @onc_ce as Paul G. Richardson, MD (@DanaFarber) presented the Ph 3 #SUCCESSOR_2 primary analysis!

[@onc_ce @onc_ce]

17) Early clinical data with #mezigdomide+#dexamethasone in triple-class-refractory #RRMM showed an ORR of 40.6%, median PFS of 4.4 months, & median DOR of 7.6 months, with neutropenia & infection among the key toxicities.

🔓 https://t.co/hiBAioMTr3

[@onc_ce @onc_ce]

15) Compared with earlier #IMiDs, #mezigdomide was designed for potent and sustained Ikaros/Aiolos degradation, with pharmacodynamic data showing maximal #Aiolos degradation around 3 hours & suppression through 24 hours.

[ibd_ce @ibd_ce]

Check out this 🆓webinar from founding @ibd_ce faculty @GI_PharmD on June 27. Presented by @ASHPOfficial and you can register now at https://t.co/0wrErFLWne. Don't miss it!

[Aline Charabaty, MD, FACG, AGAF @DCharabaty]

☯️Passionate about #IBD & #InterventionalEndoscopy?

This🔥@ASGEendoscopy course #InterventionalIBD led by @SchairerIBDMD @GKochharMD is 4 you!

✅Stricture Dilation, Stricturotomy, Stenting
✅EUS
✅Fistula endo Rx
& more

🔗https://t.co/V6eFzScLm6

In person/💻
Didactic/hands-on

[Shubha Bhat, PharmD @GI_PharmD]

📣 Looking for #CE, #CME credit?

✅ Out this #tweetorial on #IBD and #biosimilars! Had a great time putting this together with @academiccme @AmanRheumPharm and Dr. Cheiftez!

[Ali Rezaie MD MSc @AliRezaieMD]

There are simply too many diseases which can cause abdominal discomfort and change in bowel habits without any obvious endoscopic or radiologic findings.
Without a heavy focus on biomarker development to subdivide IBS, the field will not advance dramatically in future.
#IBSAwarenessMonth

[Waqqas Afif, MD @waqqasafif]

Excellent initiative to start this peer-reviewed, open access, journal by Canadian IBD clinicians. Thanks to the editorial board @TBessissow @GI_JeffMD @SeowCynthia @RPanaccione and the generous support from @TakedaPharma

https://t.co/CfqIHszIDg

[Shomron Ben-Horin @ShomronH]

Last year news, but not sure we IBD community captured this: Adalimumab beneficial as add-on in pilot RCT of major depression pts. Similar signal with IFX before. Should pts with IBD+depression get aTNF as 1st line?

https://t.co/EMwlOkUM1L